|
Yale Cancer Center NCTN
|
5U10CA180826-03
|
$551,500
|
$27,575
|
HOCHSTER, HOWARD
|
YALE UNIVERSITY
|
|
Winship Cancer Institute, National Clinical Trials Network Lead Academic Particip
|
5U10CA180864-03
|
$542,807
|
$10,856
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
|
Validation of Methylated Vimentin as a Diagnostic Test for Barrett's Esophagus
|
1UH2CA205105-01
|
$346,395
|
$346,395
|
WILLIS, JOSEPH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
|
5U10CA180870-03
|
$645,976
|
$8,075
|
GERBER, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
|
3U10CA180870-02S1
|
$50,000
|
$625
|
SCHILLER, JOAN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
|
5U10CA180858-03
|
$1,192,600
|
$14,908
|
ENG, CATHY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-28S1
|
$198,450
|
$1,985
|
LAWRENCE, THEODORE
|
UNIVERSITY OF MICHIGAN
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-28S2
|
$499,325
|
$4,993
|
LAWRENCE, THEODORE
|
UNIVERSITY OF MICHIGAN
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
4P30CA046592-28
|
$6,209,909
|
$62,099
|
LAWRENCE, THEODORE
|
UNIVERSITY OF MICHIGAN
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
2P30CA134274-09
|
$2,259,773
|
$90,391
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-09S1
|
$124,964
|
$4,999
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-09S2
|
$200,219
|
$8,009
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-09S3
|
$629,550
|
$25,182
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Understanding Esophageal Adenocarcinoma Progression Using Inflammatory and Neoplastic Extracellular Matrix Hydrogels
|
1F31CA210694-01
|
$39,834
|
$39,834
|
SALDIN, LINDSEY
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
UGI cancer studies - other
|
ZIA CP000185-10319
|
$75,564
|
$75,564
|
Dawsey, Sanford
|
DCEG (NCI)
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$353,472
|
$17,674
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Translational Research in GI Cancer
|
3P50CA130810-05S2
|
$1,100,000
|
$11,000
|
BRENNER, DEAN
|
UNIVERSITY OF MICHIGAN
|
|
Translational Research in Cancer
|
3P30CA056036-17S1
|
$117,000
|
$1,170
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
4P30CA056036-17
|
$2,807,751
|
$28,078
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
TissueCypher Testing for Risk Assessment in Barretts Esophagus
|
5R44CA192416-02
|
$606,395
|
$606,395
|
CRITCHLEY-THORNE, REBECCA
|
CERNOSTICS, INC.
|
|
The role of mutant p53 and endocytic recycling in ESCC invasion and metastasis
|
1F32CA206264-01
|
$54,294
|
$54,294
|
LENTO, ASHLEY
|
UNIVERSITY OF PENNSYLVANIA
|
|
The role of AXL-ABL axis in Barrett's carcinogenesis
|
1R01CA193219-01A1
|
$134,527
|
$134,527
|
BELKHIRI, ABBES
|
VANDERBILT UNIVERSITY
|
|
The role of AXL-ABL axis in Barrett's carcinogenesis
|
6R01CA193219-02
|
$216,787
|
$216,787
|
BELKHIRI, ABBES
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
The role of Aurora Kinase A in Upper Gastrointestinal Adenocarcinomas
|
5R01CA131225-09
|
$355,500
|
$177,750
|
EL-RIFAI, WAEL
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
The Molecular Functions of APE1 in Barrett's Tumorigenesis
|
5R01CA206563-03
|
$431,700
|
$431,700
|
EL-RIFAI, WAEL
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
The Golestan Cohort Study
|
ZIA CP000185-10361
|
$137,842
|
$82,705
|
Abnet, Christian
|
DCEG (NCI)
|
|
TGIB Surgical Oncology Fellowship Program
|
ZIE BC 011542
|
$1,075,385
|
$215,077
|
Schrump, David
|
CCR (NCI)
|
|
Synergy of Bile Acid and Cigarette Smoke on Esophageal Cancer Progression
|
ZIA BC 011631
|
$288,746
|
$288,746
|
Ripley, Robert
|
CCR (NCI)
|
|
SWOG Network Group Operations Center of the NCTN
|
3U10CA180888-03S1
|
$308,895
|
$6,178
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
SWOG Network Group Operations Center of the NCTN
|
5U10CA180888-03
|
$5,204,873
|
$104,097
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Stem Cells And The Origins of Barrett's Esophagus
|
3U54CA163004-05S2
|
$236,993
|
$236,993
|
WANG, TIMOTHY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER
|
4P50CA127003-09
|
$2,162,000
|
$475,640
|
FUCHS, CHARLES
|
DANA-FARBER CANCER INST
|
|
SEVERABLE FUNDING FOR NCI-FREDERICK
|
261200800001E
|
$248,730,791
|
$153,883
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
Research Management and Support
|
RMS ES 2016
|
$320,501,735
|
$458,947
|
N/A
|
National Institutes of Health
|
|
Randomized Placebo-Controlled Trial of a Gastrin Receptor Antagonist in Barretts Esophagus
|
5R03CA186218-02
|
$81,186
|
$81,186
|
ABRAMS, JULIAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Radioactive Stents for Brachytherapy of Esophageal Cancers
|
5R44CA171687-03
|
$748,826
|
$748,826
|
PENG, YONGREN
|
XL SCI-TECH, INC.
|
|
Radiation dose- response and second primary cancers of stomach, esophagus, and p
|
ZIA CP010131-04134
|
$79,021
|
$11,853
|
Morton, Lindsay
|
DCEG (NCI)
|
|
Quantitative PET/CT Analysis to Improve Evaluation of Tumor Response
|
4R01CA172638-04
|
$318,513
|
$318,513
|
LU, WEI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Precision Personalized Proton Therapy through Advanced Imaging Technology
|
5K07CA193916-02
|
$106,056
|
$26,514
|
GROGG, KIRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Postmenopausal women's alcohol study
|
ZIA CP000101-10336
|
$40,511
|
$2,026
|
Taylor, Philip
|
DCEG (NCI)
|
|
Plastic States Associated with Cellular Stress and Malignancy: Insights for Prevention and Treatment of Lethal Metaplastic Cancers
|
1R35CA197694-01
|
$929,349
|
$306,685
|
TLSTY, THEA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
PANGEA: Personalized Antibodies for GastroEsophageal Adenocarcinoma Pilot Trial
|
5K23CA178203-03
|
$168,507
|
$42,127
|
CATENACCI, DANIEL
|
UNIVERSITY OF CHICAGO
|
|
OSU as Network Lead Academic Participating Site for the NCI NCTN
|
5U10CA180850-03
|
$1,384,556
|
$34,614
|
GOLDBERG, RICHARD
|
OHIO STATE UNIVERSITY
|
|
Oral microbiome in esophageal adenocarcinoma
|
5U01CA182370-03
|
$539,256
|
$539,256
|
PEI, ZHIHENG
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Optical Biopsy Using Optical Coherence Tomography
|
5R01CA075289-19
|
$288,576
|
$288,576
|
FUJIMOTO, JAMES
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Oncogenic Function of Ca2+ Channel Orai1 in Esophageal Carcinogenesis
|
5R01CA185055-02
|
$335,862
|
$335,862
|
PAN, ZUI
|
OHIO STATE UNIVERSITY
|
|
NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
|
3U10CA180868-03S1
|
$63,524
|
$1,588
|
WOLMARK, NORMAN
|
NRG ONCOLOGY FOUNDATION, INC.
|
|
NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
|
3U10CA180868-03S2
|
$750,000
|
$18,750
|
WOLMARK, NORMAN
|
NRG ONCOLOGY FOUNDATION, INC.
|
|
NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
|
5U10CA180868-03
|
$12,115,890
|
$302,897
|
WOLMARK, NORMAN
|
NRG ONCOLOGY FOUNDATION, INC.
|
|
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma
|
5R01CA187119-02
|
$384,872
|
$384,872
|
BASS, ADAM
|
DANA-FARBER CANCER INST
|
Total relevant funding to Esophagus for this search: $26,226,485
|